Indeed, the use of mevalonate pathway antagonist lovastatin has shown significant efficacy in reducing the proliferation of ovarian cancer cells in mouse xenograft models, regulating the expression of several essential genes involved in DNA replication, Rho/PLC signaling, glycolysis, and cholesterol biosynthesis pathways [146]. Here, RHO is linked to ovarian carcinoma.